International Edition
Latest News
Health

CVS: GLP-1 Drugs Save Money Below $350/Month

CVS Health announced on November 14 that employers could achieve a financial break-even point on GLP-1 weight-loss medications if the drugs were priced below $350 per month. The pharmacy giant’s internal analysis, which examines claims data for patients…

CVS: GLP-1 Drugs Save Money Below 0/Month

CVS Health announced on November 14 that employers could achieve a financial break-even point on GLP-1 weight-loss medications if the drugs were priced below $350 per month.

The pharmacy giant’s internal analysis, which examines claims data for patients with obesity and diabetes, suggests that current market prices are too high for medical savings to offset the cost of the prescriptions.

While the use of medications like Ozempic, Mounjaro, Wegovy, and Zepbound is associated with a 10% to 12% reduction in emergency room visits, the high cost of the drugs remains a barrier to broader corporate coverage, according to Reuters.

Employers Restrict Drug Access as Premiums and Costs Rise

The financial pressure on health plan sponsors is intensifying as premiums are projected to rise by over 9% in 2027. According to data from the Employee Benefit Research Institute, employers currently pay between $617 and $766 monthly for these medications, exceeding the suggested break-even threshold.

Consequently, corporations are increasingly restricting access to the drugs. A survey by the consultant WTW found that 53% of employers covered weight-loss medications this year, a decline from 57% the previous year, as reported by USA Today. About 14% of companies have already moved to drop or plan to drop GLP-1 coverage entirely by 2027, according to the New York Post.

CVS: GLP-1 Drugs Save Money Below $350/Month
Photo: Yahoo Finance

Hospitalizations Decrease While Net Costs for Patients Rise

CVS Health’s analysis tracked 60,000 patients in the first year and 20,000 in the second, finding that long-term use increases hospital visits. For the 4,000 patients who remained on the medication after three years, hospitalizations decreased by 34% to 42%.

Despite these clinical benefits, the net financial impact remained negative for plan sponsors over the three-year period. While medical bills dropped by $9,400 per person, prescription spending increased by $13,300, resulting in a net cost increase of $3,900 per patient. "The higher-risk the person is, the quicker you get to a return on investment," said Dr. Amy Compton-Phillips, chief medical officer at CVS Health.

Manufacturers Could Lower Prices for Employers

Compton-Phillips said that current direct-to-consumer prices for cash-pay customers—which range from $299 to $349—suggest that manufacturers could lower prices for employers while remaining profitable. “I hope that we can reach that price sooner rather than later,” she told the New York Post.

CVS: GLP-1 Drugs Save Money Below $350/Month
Photo: Buffalo News

The U.S. government is already testing the feasibility of lower costs, having secured a deal with Eli Lilly and Novo Nordisk to pay $245 per month for injectable GLP-1 drugs as part of an 18-month pilot program for Medicare beneficiaries.

However, whether drug manufacturers will voluntarily lower prices for the broader private employer market remains unknown, as CVS declined to comment on the average prices they currently pay for the drugs.

Frequently Asked Questions

Why are employers dropping coverage for GLP-1 drugs?
Companies cite the high cost of the medications as the primary reason for dropping coverage, as current pricing often exceeds the savings gained from reduced medical services. According to a WTW survey, 30% of companies that still cover the drugs are currently considering eliminating that benefit.

How does patient health status affect the return on investment?
The financial benefit depends on the patient’s baseline risk. “An older person with diabetes is going to have a higher risk for hospitalization than a younger person who is obese without diabetes” said Dr. Compton-Phillips, chief medical officer at CVS Health.

What is the current status of the federal pilot program?
The U.S. government is conducting an 18-month pilot program to evaluate the cost-effectiveness of GLP-1 drugs for Medicare beneficiaries aged 65 and older or those with disabilities. Under this agreement, the government pays $245 per month for the treatments.

About the author: Dr Natalie Singh - Health Editor

Board‑certified internal‑medicine physician and MPH. Natalie authored peer‑reviewed studies on infectious disease and served as medical editor. “Dr. Natalie Singh delivers evidence‑based health news, medical breakthroughs, and expert wellness guidance.”